Allogene Therapeutics Reports First Quarter 2023 Financial R

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure... | May 3, 2023

Related Keywords

Illinois , United States , Chicago , American , David Chang , Christine Cassiano , Allogene Allo , Timothy Moore , American Association Of Cancer Research , Linkedin , Drug Administration , American Association For Cancer Research , Allocart Program , Allogene Therapeutics Inc , Nasdaq , American Society Of Clinical Oncology , Enrollment Ongoing , First Potentially Pivotal Phase , Refractory Largeb Cell , Support Licensure , Lymphodepleting Agent , American Society , Clinical Oncology , Annual Meeting Presentation , Interim Phase , Renal Cell Carcinoma , American Association , Cancer Research , Annual Meeting , Provide Proof Of Concept , Partial Response Following , Single Infusion , Patients Had Previously Progressed , Standard Therapies , Immune Checkpoint Inhibitor , Cell Therapy Pioneer Timothy Moore , Chief Technical , Cash Equivalents , Webcast Scheduled , Chief Executive Officer , Annual Meeting June , Executive Vice President , South San Francisco , Private Securities Litigation Reform Act , Exclusive License , Collaboration Agreement , Annual Report , Quarterly Report , Allogene Therapeutics , Months Ended March , Investor Contact , Nc Stock Exchange , News , Information , Press Release , Enrollment , Ngoing , N , First , Potentially , Pivotal , Hase , , Allogeneic , Ear , Barge , Fell , Ymphomainitiated , Xpand , Trial , O , Upport Allo Us0197701065 ,